Docetaxel plus cisplatin and bevacizumab for untreated patients with advanced/metastatic non-squamous non-small-cell lung cancer: a multicenter phase II study of the Hellenic Oncology Research Group
| Autor: | Leonidas Chelis, Sophia Agelaki, A. Kotsakis, George Samonis, L. Vamvakas, A. Soultati, Nikolaos K. Kentepozidis, P. Papakotoulas, Z. Zafiriou, M. Agelidou, V. Georgoulias, Ch. Christophylakis |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Adult
Male Oncology Cancer Research medicine.medical_specialty Lung Neoplasms Bevacizumab medicine.medical_treatment Phases of clinical research Angiogenesis Inhibitors Antineoplastic Agents Docetaxel Kaplan-Meier Estimate Antibodies Monoclonal Humanized Toxicology Medication Adherence Carcinoma Non-Small-Cell Lung Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Pharmacology (medical) Neoplasm Metastasis Lung cancer Survival analysis Aged Pharmacology Cisplatin Chemotherapy business.industry Middle Aged medicine.disease Antineoplastic Agents Phytogenic Survival Analysis Regimen Treatment Outcome Female Taxoids business medicine.drug |
| Zdroj: | Cancer Chemotherapy and Pharmacology. 71:605-612 |
| ISSN: | 1432-0843 0344-5704 |
| DOI: | 10.1007/s00280-012-2037-1 |
| Popis: | The docetaxel/cisplatin (DC) combination is an active regimen against advanced/metastatic non-small-cell lung cancer (NSCLC), and bevacizumab (B) improves the efficacy of frontline chemotherapy. This phase II study was designed in order to explore the efficacy and safety of DCB regiment in this setting.Chemotherapy-naïve patients (n = 48) with measurable, histologically confirmed non-squamous, IIIB (wet)/IV NSCLC, and PS 0-2 were eligible. Patients received D (75 mg/m(2) IV), C (80 mg/m(2) IV), and B (15 mg/kg IV) every 3 weeks. Maintenance of bevacizumab was not mandatory.Complete and partial responses were achieved in two (4.2%) and 14 (29.2%) patients, respectively [overall response rate: 33.3%; 95% CI = 20.0-46.7%], whereas stable disease was documented in 14 [disease control rate = 62.5%; 95% CI = 48.8-76.2%]. The median progression-free survival was 4.4 months and the median overall survival 13.3 months. Treatment-related grade 3 or 4 hematologic adverse events were leukopenia, neutropenia, and anemia in 8.4, 18.7, and 2.1% of the patients, respectively. Febrile neutropenia occurred in three (6.3%) patients. Bleeding was documented in 4% of the patients, thrombotic episodes in 8%, and proteinuria in 3%. There was one treatment-related death.Frontline DCB in patients with advanced non-squamous NSCLC is an active regimen with manageable toxicity and merits to be further investigated. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink